Study of Erlotinib in Combination With Dasatinib

Advanced Cancer Clinical Trial

Official title:

A Phase I Dose-Escalation Study of Erlotinib in Combination With Dasatinib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00895128
• Other study ID #: 2008-0555
• Secondary ID: NCI-2012-01632
• Status: Completed
• Phase: Phase 1
• First received: May 6, 2009
• Last updated: July 10, 2015
• Start date: April 2009

Study information

• Verified date: July 2015
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical research study is to find the highest tolerable dose of Tarceva (erlotinib hydrochloride) that can be given in combination with Sprycel (dasatinib). The safety of this drug combination will also be studied.

Description:

The Study Drugs:

Erlotinib hydrochloride and dasatinib are both designed to block proteins that are thought to cause cancer cells to grow. These drugs may help slow the growth of tumors.

Study Drug Dose Level:

If you are found to be eligible to take part in this study, you will be assigned to a dose level of erlotinib hydrochloride and dasatinib based on when you joined the study. Up to 4 dose levels of this study drug combination will be tested. There will be 3-6 participants enrolled at each dose level of the study drug combination.

The first group of participants will receive the lowest dose level of erlotinib hydrochloride (Group 1). If all of Group 1 tolerate that dose level, the next group (Group 2) will receive a higher dose. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen (Groups 2-4). This will continue until the highest tolerable dose of the study drug combination is found. However, if Group 1 did not tolerate the first dose level, the next group will receive a lower dose (called Dose Level -1). If that dose level is still intolerable, the third group will receive an even lower dose (called Dose Level -2).

The dose of dasatinib will be based in which group you in. Groups 1 and 3 will receive a lower dose and Groups 2 and 4 will receive a higher dose.

After the highest tolerable dose is found, up to an additional 10 participants, called the "expansion group," will receive the study drug combination at that dose.

Study Drug Administration:

Erlotinib hydrochloride will be taken by mouth 1 time a day every day. You should take erlotinib hydrochloride on an empty stomach either 1 hour before eating or 2 hours after eating.

Depending on which dose level you are assigned to, you will also take dasatinib by mouth 1 or 2 times a day every day.

Each cycle is 28 days.

Study Visits:

You will have a single study visit before each cycle. At these visits, the following tests and procedures will be performed:

• Your performance status will be recorded.

• You will be asked to list any drugs you may be taking, including over-the-counter drugs.

• You will be asked about any symptoms you may have.

• You will have a physical exam, including measurement of your vital signs.

• Blood (about 2 teaspoons) will be drawn for routine tests.

• Blood (about 2 teaspoons) will be drawn for pharmacodynamic (PD) testing. PD testing is used to look at how the level of study drug in your body may affect the disease.

After the first 2 cycles and then every 2 to 3 cycles, you will have a CT or MRI scan to check the status of the disease.

Length of Study:

You may continue taking the study drugs for as long as you are benefitting. You will be taken off study if the disease gets worse or intolerable side effects occur.

Follow-up Visit:

About 30 days after the last dose of study drugs, you will have a follow-up visit. You will be asked to return any unused study drug. At this visit, the following tests and procedures will be performed:

• Your performance status will be recorded.

• You will be asked to list any drugs you may be taking, including over-the-counter drugs.

• You will be asked about any symptoms you may have.

• You will have a physical exam, including measurement of your vital signs.

• Blood (about 2 teaspoons) and urine will be collected for routine tests.

This is an investigational study. Dasatinib and erlotinib hydrochloride are both FDA approved and commercially available. Dasatinib is FDA approved for the treatment of acute lymphoid leukemia (ALL) and chronic myeloid leukemia (CML). Erlotinib hydrochloride is FDA approved for the treatment of lung cancer and pancreatic cancer. The use of these drugs together is investigational.

Up to 48 participants will take part in this study. All will be enrolled at M. D. Anderson.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with pathologically confirmed advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or who have had no standard therapy that induces a CR rate of at least 10% or improves survival by at least three months.

2. Measurable or non-measurable disease.

3. Patients must be >/= 6 wks beyond treatment with a nitrosourea or mitomycin-C, >/= 4 wks beyond other chemotherapy or external beam radiation therapy (XRT), and must have recovered to </= Grade 1 toxicity for any treatment-limiting toxicity resulting from prior therapy. (Exception: patients may have received palliative low dose XRT one week before treatment provided it is not given to the only targeted lesions).

4. (continued from above) Also, patients who have received non-chemotherapeutic biological agents will need to wait at least 5 half-lives or 4 wks, whichever is shorter, from the last day of treatment.

5. Eastern Cooperative Oncology Group (ECOG) performance status </= 2 (Karnofsky >/= 60%)

6. Patients must have normal organ and marrow function defined as: absolute neutrophil count >/=1,000/mL; platelets >/=50,000/mL; creatinine </= 2 X upper limit of normal (ULN); total bilirubin </= 2.0; ALT(SGPT) </= 3 X ULN; Exception for patients with liver metastasis: total bilirubin </= 3 x ULN; ALT(SGPT) </= 5 X ULN.

7. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose.

8. Ability to understand and the willingness to sign a written informed consent document

9. For the MTD expansion cohort, patients will be eligible if they meet one of the following criteria: (I) Have an EGFR-sensitive mutation and have been previously treated with EGFR inhibitor therapy but have subsequently developed resistance, OR (II) Have an EGFR-resistant mutation, OR (III) Do not have an EGFR mutation, but have benefited from EGFR inhibitor therapy (including either >/=4 months of stable disease [SD] OR a >/= partial response [PR]).

Exclusion Criteria:

1. Patients with uncontrolled concurrent illness, including but not limited to: ongoing or active infection; altered mental status or psychiatric illness/social situations that would limit compliance with study requirements and/or obscure study results.

2. Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg on medication).

3. Patients with clinically significant cardiovascular disease: history of cardiovascular accident (CVA) within 6 months, myocardial infarction or unstable angina within 6 months, or unstable angina pectoris.

4. Patients with colorectal carcinoma with tumors that demonstrate a Kirsten rat sarcoma (KRAS) mutation.

5. Pregnant or lactating women.

6. Patients with a history of bone marrow transplant within the previous two years.

7. Patients with a known hypersensitivity to any of the components of the drug products.

8. Patients who will be on treatment arm consisting of erlotinib and dasatinib should not be taking any drugs that are potent inhibitors or inducers of CYP34A

9. Patients unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugs.

10. Patients with major surgery within 30 days prior to entering the study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Cancer
• Neoplasms

Intervention

Drug:
• Erlotinib Hydrochloride
Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
• Dasatinib
Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.

Locations

Country	Name	City	State
United States	University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate	Tumor response defined as one or more of the following: (1) stable disease for more than or equal to 4 months, (2) decrease in measurable tumor (sentinel lesions) by more than or equal to 20% by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, (3) decrease in tumor markers by more than or equal to 25% (for example, a >/= 25% decrease in cancer antigen 125 (CA125) for patients with ovarian cancer), or (4) a partial response according to the Choi criteria, i.e. decrease in size by 10% or more, or a decrease in the tumor density, as measured in Hounsfield units (HU), by more than or equal to 15%.	Response Evaluation after two 28-day cycles.	No
Secondary	Maximum Tolerated Dose (MTD)	MTD defined as highest dose studied in which incidence of dose limiting toxicity (DLT) was less than 33%. DLT defined as any Grade 3 or 4 non-hematologic toxicity defined in the NCI CTC v3.0, even if expected and believed related to study medications (except nausea and vomiting responsive to appropriate regimens or alopecia), any Grade 4 hematologic toxicity lasting 2 weeks or longer (as defined by the NCI-CTCAE), despite supportive care; any Grade 4 nausea or vomiting > 5 days despite maximum anti-nausea regimens, and any other Grade 3 non-hematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome; or any severe or life-threatening complication or abnormality not defined in NCI-CTCAE that is attributable to the therapy.	28 days	Yes

External Links

•   University of Texas MD Anderson Cancer Center Website